AK106-001616

DB16058InvestigationalSmall molecule

AK106-001616 is under investigation in clinical trial NCT01285752 (A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)).

Chemical structure of AK106-001616
Mechanism
Curator reviewed
Formula / weight
C26H25N3O3 · 427.504 g/mol (avg)
Code names
AK-106 · AK106-001616

Resolves to

Compound
UNIII2CST2BV1QCAS590416-75-4ChEMBLCHEMBL4297481
Structure
InChIKeyULNYPYSSPODXCS-UHFFFAOYSA-NSMILESCN1N=CC2=C1C=CC(=C2)C1=C(OC2CC3=C(C2)C=CC=C3)C(N)=CC(CCC(O)=O)=C1
Targets
P47712PLA2G4A
Transporters
Q4U2R8SLC22A6Q8TCC7SLC22A8

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2TransportersSubstrate / inhibitor direction, not just membership
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with AK106-001616, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In